ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Kyowa Hakko Kogyo (PK)

Kyowa Hakko Kogyo (PK) (KYKOF)

14,425
0,00
(0,00%)
Geschlossen 11 Juni 10:00PM

Kyowa Hakko Kogyo (PK) (KYKOF) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
14,425
( - )
Gebot
13,22
Fragen
15,76
Volumen
3.900
0,00 Tagesbereich 0,00
12,42 52-Wochen-Bereich 18,00
Marktkapitalisierung
Handelsende
14,425
Handelsbeginn
-
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
US$ 1.500.690
Ausgegebene Aktien
523.486.836
Dividendenrendite (LTM)
62 (2,94%)
Kurs-Gewinn-Verhältnis
16,96
Gewinn pro Aktie (EPS)
139,27
Erlöse (LTM)
510,57B
Nettogewinn (LTM)
72,91B

Über Kyowa Hakko Kogyo (PK)

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia w... Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Hauptsitz
Chiyoda, Japan
Gegründet
2026
Kyowa Hakko Kogyo (PK) is listed in the Healthcare sector of the OTC Markets with ticker KYKOF. The last closing price for Kyowa Hakko Kogyo (PK) was US$14,43. Over the last year, Kyowa Hakko Kogyo (PK) shares have traded in a share price range of US$ 12,42 to US$ 18,00.

Kyowa Hakko Kogyo (PK) currently has 523.486.836 shares in issue. The market capitalisation of Kyowa Hakko Kogyo (PK) is US$7,55 billion. Kyowa Hakko Kogyo (PK) has a price to earnings ratio (PE ratio) of 16.96.

KYKOF Neueste Nachrichten

Keine Nachrichten vorhanden.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
4-0.649222-4.3068358685415.07422215.07422215.074222180015.074222CS
12-0.625-4.1528239202715.0515.07422214.425633614.47053608CS
26-2.165-13.050030138616.591812.42303714.84148217CS
52-2.715-15.840140023317.141812.42194415.25766054CS
156-5.138-26.263865460319.56322.21412.316202316.81838922CS
260-21.6443-60.007541039136.069337.33212.316223220.82925811CS

KYKOF - Frequently Asked Questions (FAQ)

What is the current Kyowa Hakko Kogyo (PK) share price?
The current share price of Kyowa Hakko Kogyo (PK) is US$ 14,425
How many Kyowa Hakko Kogyo (PK) shares are in issue?
Kyowa Hakko Kogyo (PK) has 523.486.836 shares in issue
What is the market cap of Kyowa Hakko Kogyo (PK)?
The market capitalisation of Kyowa Hakko Kogyo (PK) is USD 7,55B
What is the 1 year trading range for Kyowa Hakko Kogyo (PK) share price?
Kyowa Hakko Kogyo (PK) has traded in the range of US$ 12,42 to US$ 18,00 during the past year
What is the PE ratio of Kyowa Hakko Kogyo (PK)?
The price to earnings ratio of Kyowa Hakko Kogyo (PK) is 16,96
What is the cash to sales ratio of Kyowa Hakko Kogyo (PK)?
The cash to sales ratio of Kyowa Hakko Kogyo (PK) is 2,42
What is the registered address of Kyowa Hakko Kogyo (PK)?
The registered address for Kyowa Hakko Kogyo (PK) is Otemachi Financial City Grand Cube, Chiyoda, Tokyo, 100-0004
What is the Kyowa Hakko Kogyo (PK) website address?
The website address for Kyowa Hakko Kogyo (PK) is www.kyowakirin.com
Which industry sector does Kyowa Hakko Kogyo (PK) operate in?
Kyowa Hakko Kogyo (PK) operates in the Pharmaceuticals sector

KYKOF Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen